Cathy Eng, VICC Associate Director, Strategic Relations and Research Partnerships at Vanderbilt-Ingram Cancer, shared a post on X:
“Important article: Cancer related thrombosis.
2.5 mg PO BID Apixaban = 5.0 mg po BID x 12M for primary endpoint of recurrent thrombosis.”
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé et al.
